Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B).

Yang, James Chih-Hsin; Ohe, Yuichiro; Chiu, Chao-Hua; Ou, Xiaoling; Cantarini, Mireille; Jänne, Pasi A; Hartmaier, Ryan J; Ahn, Myung Ju

Yang, James Chih-Hsin; Ohe, Yuichiro; Chiu, Chao-Hua; Ou, Xiaoling; Cantarini, Mireille; Jänne, Pasi A; Hartmaier, Ryan J; Ahn, Myung Ju.

Afiliação

Yang JC; National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan.
Ohe Y; National Cancer Center Hospital, Tokyo, Japan.
Chiu CH; Taipei Veterans General Hospital, Taipei, Taiwan.
Ou X; Early Clinical Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
Cantarini M; Late Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
Jänne PA; Lowe Center for Thoracic Oncology and the Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Hartmaier RJ; Translational Medicine, Oncology R&D, AstraZeneca, Waltham, Massachusetts.
Ahn MJ; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Clin Cancer Res ; : OF1-OF10, 2022 Jun 23.

Article em En | MEDLINE | ID: mdl-35735998

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Taiwan

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google